GLPwatch
Papers (10410)
Page 144 of 174, ranked by citation count.
- [Exendin-4 promotes paracrine action of adipose-derived stem cells through PI3K/Akt signaling pathways].
- Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity.
- Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.
- Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
- Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
- Person-centered choice of anti-obesity pharmacotherapy.
- Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.
- Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study.
- Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.
- Influence of pH, Buffering Capacity, Ionic Strength, Bile Salts, and Model Drugs on Micellization Behaviour of Salcaprozate Sodium in Physiological Range pH Buffers.
- The revolution of the anti-diabetic drugs in cardiology.
- The Potential Weight Loss Benefits Of Tirzepatide: A Double-Edged Sword?
- [Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review].
- GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review.
- Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists.
- Depot-specific differences and heterogeneity of adipose-derived stem cells in diet-induced obesity.
- Liraglutide preserves endothelial function in ophthalmic arteries of septic mice via prevention of oxidative stress.
- Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice.
- New Drug Capsule: Tirzepatide.
- [Influences of exendin-4 on the secretion function of islet beta cells from rats in the early stage of severe scald].
- Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon- Like Peptide-1 Receptor Agonists - A Review.
- Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.
- Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex-sumo wrestler.
- Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis.
- Obesity Management in Youth with Duchenne Muscular Dystrophy: A Review of Metformin and Alternative Pharmacotherapies.
- Comparison of PET/CT using <sup>68</sup>Ga-NOTA-Exendin-4 with <sup>68</sup>Ga-DOTATATE, <sup>18</sup>F-FDG, and conventional imaging in the localization of insulinomas.
- Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.
- A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats.
- ADDITION OF DULAGLUTIDE FOR A HIGH-DOSE INSULIN REQUIRING PATIENT WITH TYPE 2 DIABETES MELLITUS: A REMARKABLE RESPONSE.
- GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023.
- Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.
- Drug-induced lesions of the oesophageal mucosa.
- Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.
- [Comments on current guidelines of type 2 diabetes mellitus treatment].
- Semaglutide in weight management.
- Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?
- Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes.
- Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.
- Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study.
- Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
- Integrating micro-needle jet injection and sustained GLP-1 therapy with structured feeding: a comprehensive strategy for obesity management.
- Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity.
- Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.
- GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.
- [Dyslipidemia and obesity 2011. Similarities and differences].
- Dulaglutide for type 2 diabetes.
- Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.
- Life-Threatening Ventricular Fibrillation Linked to High-Dose Tirzepatide-Induced Gastrointestinal Side Effects.
- Pharmacologic options for the treatment of overweight and obesity.
- Substitution of insulin by exenatide in bad controlled type 2 diabetic patients: efficacy and predictive factors.
- Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective.
- Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product.
- EHR Data Suggest Tirzepatide Outdoes Semaglutide for Weight Loss.
- Atherosclerotic features in patients with heart failure.
- Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
- Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study.
- Trends and projections of overweight and obesity among midlife women in the United States, 1990-2050: A sub‑study of the Global Burden of Disease 2021.
- [Successful treatment of KCNJ11 neonatal diabetes without insulin].